Zobrazeno 1 - 10
of 58
pro vyhledávání: '"D. L. Clarke-Pearson"'
Publikováno v:
Obstetrics & Gynecology. 86:486-490
To determine whether the poor prognosis of black women with endometrial adenocarcinoma is due to racial differences in the interval between the onset of abnormal uterine bleeding and hysterectomy.Clinical records of all 219 patients (176 white, 39 bl
Autor:
A, Nicolaides, S Z, Goldhaber, G L, Maxwell, N, Labropoulos, D L, Clarke-Pearson, T H, Tyllis, M B, Griffin
Publikováno v:
International angiology : a journal of the International Union of Angiology. 27(6)
In moderate to high-risk general surgical patients, the cost effectiveness of mechanical prophylaxis for venous thromboembolism (VTE) is uncertain. Therefore, we determined the costs and savings of intermittent pneumatic compression (IPC) plus gradua
Autor:
Daohai Yu, Andrew Berchuck, Mark W. Dewhirst, Carol A. Hahn, E. L. Jones, J. T. Soper, L. R. Prosnitz, Ivan Spasojevic, Laura J. Havrilesky, William P. Petros, D. L. Clarke-Pearson, Angeles Alvarez Secord
Publikováno v:
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 21(4)
A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasation
Autor:
S L, Clifford, C P, Kaminetsky, F D, Cirisano, R, Dodge, J T, Soper, D L, Clarke-Pearson, A, Berchuck
Publikováno v:
American journal of obstetrics and gynecology. 176(6)
OBJECTIVE: This study was conducted to determine whether overexpression of the p53 tumor suppressor gene is associated with poor outcome in early-stage endometrial cancers and whether a racial difference in the frequency of p53 overexpression contrib
Autor:
W P, McGuire, W J, Hoskins, M F, Brady, P R, Kucera, E E, Partridge, K Y, Look, D L, Clarke-Pearson, M, Davidson
Publikováno v:
Seminars in oncology. 24(1 Suppl 2)
This prospective study compared the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin with the standard therapy of cyclophosphamide/cisplatin in women with suboptimal stage III and stage IV ovarian cancer. O
Autor:
George A. Omura, David G. Mutch, M L Berman, J A Blessing, D L Clarke-Pearson, L Vaccarello, B Anderson
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(1)
PURPOSE Cisplatin, mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cispl
Autor:
W P, McGuire, W J, Hoskins, M F, Brady, P R, Kucera, E E, Partridge, K Y, Look, D L, Clarke-Pearson, M, Davidson
Publikováno v:
Seminars in oncology. 23(5 Suppl 12)
Administration of an alkylating agent plus a platinum coordination complex is standard therapy for advanced epithelial ovarian cancer in the United States. The most commonly used combination is cyclophosphamide/ cisplatin; however, the benefit of thi
Autor:
D. L. Clarke-Pearson, L. N. Abaid
Publikováno v:
Obstetrics & Gynecology. 119:872
Publikováno v:
Obstetrics and gynecology. 84(6)
To evaluate factors influencing survival and compare current classification systems in women treated for malignant gestational trophoblastic tumor.A consecutive series of 454 women treated between 1968-1992 was reviewed retrospectively to identify po
Publikováno v:
Obstetrics and gynecology. 84(5)
To evaluate the utility of the serum progesterone level for discriminating pregnancy from gestational trophoblastic neoplasia.Serum progesterone levels were measured in 61 women with histories of trophoblastic disease who developed a re-elevation in